Clemens Niedner

Formycon

Under the leadership of the Frankfurt-based Taylor-Wessing partners Lars-Gerrit Lüßmann and Michael Sinhart, Formycon AG and ATHOS KG are merging their development activities in the field of so-called biosimilars, the follow-up products of biological medicines (biologics), in a long-term strategic partnership. The centrepiece of this agreement is Formycon AG’s participation in the rights of two biosimilars. The volume of the legally complex transaction (aggregate counter-performance) adds up to approximately 650 million euros.

Taylor Wessing advises Encavis AG on a sustainability-linked EUR 125,000,000 syndicated facility

The revolving credit facility contains ratings-based sustainability criteria, has a term of up to five years and was arranged by Encavis and Commerzbank. The majority of the facilities is available on a revolving basis for the purchase of projects and thus offers Encavis the possibility to spontaneously and easily broaden the portfolio of the group's own projects. In addition, a traditional working capital line with the possibility of establishing ancillary facilities is included.

Taylor Wessing advises syndicate of banks on a sustainability-linked EUR 500,000,000 syndicated facility for Symrise AG

Advised syndicate of banks on a sustainability-linked EUR 500,000,000 facility for Symrise AG. The sustainability criteria are individually tailored to the needs of the group and include the eco-efficiency of greenhouse gas emissions, the expansion of sustainable procurement processes for biological raw materials and increasing the efficiency of water consumption in arid regions.